Towerview LLC Has $4.90 Million Stake in Alumis Inc. $ALMS

Towerview LLC lessened its position in shares of Alumis Inc. (NASDAQ:ALMS) by 55.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 222,294 shares of the company’s stock after selling 272,706 shares during the quarter. Alumis accounts for approximately 3.2% of Towerview LLC’s investment portfolio, making the stock its 7th largest holding. Towerview LLC’s holdings in Alumis were worth $4,897,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Ieq Capital LLC increased its stake in Alumis by 4.1% in the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after acquiring an additional 690 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Alumis by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after purchasing an additional 979 shares during the period. Strs Ohio raised its holdings in shares of Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after buying an additional 1,500 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Alumis by 12.4% in the 4th quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after buying an additional 1,618 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after buying an additional 2,949 shares during the period.

Insider Transactions at Alumis

In other Alumis news, insider Sanam Pangali sold 5,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $28.00, for a total value of $140,000.00. Following the transaction, the insider owned 11,111 shares of the company’s stock, valued at approximately $311,108. The trade was a 31.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 33.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Citigroup reaffirmed a “buy” rating on shares of Alumis in a research note on Tuesday, May 19th. HC Wainwright lowered Alumis from a “buy” rating to a “neutral” rating and set a $25.00 price objective for the company. in a research note on Friday, May 15th. Oppenheimer lifted their price objective on Alumis from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. Finally, Morgan Stanley restated an “overweight” rating and issued a $39.00 target price on shares of Alumis in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.30.

Alumis Trading Down 5.5%

NASDAQ ALMS opened at $27.23 on Friday. Alumis Inc. has a 1-year low of $3.24 and a 1-year high of $31.35. The company has a 50 day moving average of $23.93 and a 200-day moving average of $24.03. The firm has a market cap of $3.47 billion, a price-to-earnings ratio of -13.75 and a beta of -0.73.

Alumis (NASDAQ:ALMS) last announced its earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. On average, analysts forecast that Alumis Inc. will post -2.87 earnings per share for the current year.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.